Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01316549 · ClinicalTrials.gov registry record
Study of Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation
A clinical trial, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 67
- Enrollment target
NCT01316549: Completed study, sponsored by University of California, San Francisco.
NCT01316549 is a clinical trial that has completed, run by University of California, San Francisco. The registered enrollment target is 67 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01316549 has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 67 participants
- Enrollment target
Study Summary
Fludarabine is a chemotherapy drug used extensively in bone marrow transplantation. The goal of this study is to determine what causes some children to have different drug concentrations of fludarabine in their bodies and if drug levels are related to whether or not a child experiences severe side-effects during their bone marrow transplant. The hypothesis is that clinical and genetic factors cause changes in fludarabine drug levels in pediatric bone marrow transplant patients and that high levels may cause severe side-effects.
Interventions
- DRUG Fludarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2011-01-01 |
| Est. Completion | 2016-04-30 |
What the finished NCT01316549 record still lists
NCT01316549 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 67 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Fludarabine is the first listed.
NCT01316549 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01316549 about?
NCT01316549 is a clinical study titled "Study of Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation". Fludarabine is a chemotherapy drug used extensively in bone marrow transplantation. The goal of this study is to determine what causes some children to have different drug concentrations of fludarabine in their bodies and if drug levels are related to whether or not a child experiences severe side-e...
What is the current status of trial NCT01316549?
This trial is currently completed. The enrollment target is 67 participants. The study started on 2011-01-01. Estimated completion is 2016-04-30.
What interventions are being tested in trial NCT01316549?
The interventions under investigation include: Fludarabine (DRUG).
Who is sponsoring clinical trial NCT01316549?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI